{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:40:55Z","timestamp":1767145255105,"version":"build-2238731810"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81270610"],"award-info":[{"award-number":["81270610"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700122"],"award-info":[{"award-number":["81700122"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770203"],"award-info":[{"award-number":["81770203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070178"],"award-info":[{"award-number":["82070178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200169"],"award-info":[{"award-number":["82200169"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["ZH19003"],"award-info":[{"award-number":["ZH19003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cpt.2022.09.003","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T10:19:20Z","timestamp":1666001960000},"page":"25-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Next-generation sequencing revealed factors associated with cumulative incidence of relapse and leukemia-free survival in patients with newly diagnosed acute myeloid leukemia"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0823-1412","authenticated-orcid":false,"given":"Sai","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingmin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayue","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengcheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanbo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7352-9560","authenticated-orcid":false,"given":"Liping","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3334-9113","authenticated-orcid":false,"given":"Daihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2022.09.003_bib1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/bjh.15916","article-title":"Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients","volume":"186","author":"Folta","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpt.2022.09.003_bib2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2022.09.003_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40364-020-00208-1","article-title":"AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report","volume":"8","author":"Pogosova-Agadjanyan","year":"2020","journal-title":"Biomark Res"},{"key":"10.1016\/j.cpt.2022.09.003_bib4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.cpt.2022.09.003_bib5","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1200\/JCO.19.00416","article-title":"Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: a pooled analysis of individual patient data from nine international cohorts","volume":"37","author":"Angenendt","year":"2019","journal-title":"J\u00a0\u200bClin Oncol"},{"key":"10.1016\/j.cpt.2022.09.003_bib6","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/bjh.16239","article-title":"Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia","volume":"188","author":"Linch","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpt.2022.09.003_bib7","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/bloodadvances.2018020305","article-title":"Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia","volume":"2","author":"Sakaguchi","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.cpt.2022.09.003_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/bjh.16535","article-title":"Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA","volume":"190","author":"Wang","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cpt.2022.09.003_bib9","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12935-021-02233-y","article-title":"Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia","volume":"21","author":"Fan","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.cpt.2022.09.003_bib10","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/leu.2016.207","article-title":"RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features","volume":"30","author":"Gaidzik","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.cpt.2022.09.003_bib11","doi-asserted-by":"crossref","first-page":"10782","DOI":"10.3390\/ijms221910782","article-title":"TP53 in acute myeloid leukemia: molecular aspects and patterns of mutation","volume":"22","author":"George","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpt.2022.09.003_bib12","doi-asserted-by":"crossref","first-page":"n2026","DOI":"10.1136\/bmj.n2026","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cpt.2022.09.003_bib13","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N\u00a0\u200bEngl J Med"},{"key":"10.1016\/j.cpt.2022.09.003_bib14","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood-2017-09-807438","article-title":"The impact of age, NPM1(mut), and FLT3(ITD) allelic ratio in patients with acute myeloid leukemia","volume":"131","author":"Straube","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2022.09.003_bib15","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J\u00a0\u200bClin Oncol"},{"key":"10.1016\/j.cpt.2022.09.003_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN guidelines insights: acute myeloid leukemia, version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J\u00a0\u200bNatl Compr Cancer Netw"},{"key":"10.1016\/j.cpt.2022.09.003_bib17","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMe1802610","article-title":"Clonal hematopoiesis after induction chemotherapy for acute myeloid leukemia","volume":"378","author":"Steensma","year":"2018","journal-title":"N\u00a0\u200bEngl J Med"},{"key":"10.1016\/j.cpt.2022.09.003_bib18","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood.2019004770","article-title":"Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia","volume":"135","author":"Hasserjian","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2022.09.003_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0\u200bEngl J Med"},{"key":"10.1016\/j.cpt.2022.09.003_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2022.09.003_bib21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cpt.2022.09.003_bib22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40164-019-0158-5","article-title":"Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia","volume":"9","author":"Yu","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.cpt.2022.09.003_bib23","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.21.00067","article-title":"Optimizing risk stratification in acute myeloid leukemia: dynamic models for a dynamic therapeutic landscape","volume":"39","author":"Short","year":"2021","journal-title":"J\u00a0\u200bClin Oncol"},{"key":"10.1016\/j.cpt.2022.09.003_bib24","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ajh.25553","article-title":"Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with\/without sorafenib","volume":"94","author":"Yalniz","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cpt.2022.09.003_bib25","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/ajh.26298","article-title":"Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation","volume":"96","author":"Grimm","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cpt.2022.09.003_bib26","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1038\/s41467-018-06063-x","article-title":"Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia","volume":"9","author":"Shiozawa","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpt.2022.09.003_bib27","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/s41375-020-0839-4","article-title":"Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia","volume":"34","author":"Bamopoulos","year":"2020","journal-title":"Leukemia"}],"updated-by":[{"DOI":"10.1016\/j.cpt.2023.09.006","type":"expression_of_concern","label":"Expression of concern","source":"publisher","updated":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000}}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713222000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713222000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:02:55Z","timestamp":1762650175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949713222000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2949713222000039"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2022.09.003","relation":{},"ISSN":["2949-7132"],"issn-type":[{"value":"2949-7132","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation sequencing revealed factors associated with cumulative incidence of relapse and leukemia-free survival in patients with newly diagnosed acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2022.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}